Du är här

2016-02-12

Novo Nordisk A/S: Proposed changes in composition of the Board of Directors of Novo Nordisk A/S

Bagsværd, Denmark, 12 February 2016
- The Annual General Meeting of Novo Nordisk A/S is planned to be held on
Friday 18 March 2016.

All board members elected by the Annual General Meeting are up for election.
Thomas Paul Koestler and Eivind Kolding do not seek re-election.

At the Annual General Meeting, the Board of Directors proposes re-election of
the following board members elected by the shareholders: Göran Ando
(chairman), Jeppe Christiansen (vice chairman), Bruno Angelici, Sylvie
Grégoire, Liz Hewitt and Mary Szela.

Furthermore, the Board of Directors proposes that Brian Daniels is elected as
new member to the Board of Directors.

Brian Daniels, MD, is a senior advisor with the Boston Consulting Group and
venture partner with 5AM Venture Management, LLC, both in the US. The Board
of Directors recommends election of Brian Daniels because of his extensive
experience in clinical development, medical affairs and corporate strategy
across a broad range of therapeutics areas within the pharmaceutical
industry, especially in the US.

Further information

-----------------------------------------------------------------
| Media: |
| Anne Margrethe Hauge +45 3079 3450 amhg@novonordisk.com |
| Ken Inchausti (US) +1 609 786 8316 kiau@novonordisk.com |
| Investors: |
| Peter Hugreffe Ankersen +45 3075 9085 phak@novonordisk.com |
| Daniel Bohsen +45 3079 6376 dabo@novonordisk.com |
| Melanie Raouzeos +45 3075 3479 mrz@novonordisk.com |
| Kasper Veje +45 3079 8519 kpvj@novonordisk.com |
-----------------------------------------------------------------
Company announcement No 13 / 2016

Company announcement No 13 / 2016
http://hugin.info/2013/R/1985881/728431.pdf

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novo Nordisk A/S via Globenewswire

HUG#1985881

Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.